Skip to main content

Table 4 Normalized expressions (2^(−Avg.(Delta(Ct)) of hsa-miR-181a-5p and RNU6–2 in Group 1 (CML patients responsive to imatinib therapy), and Control Group (blood donors) calculated by Gene Globe Data Analysis Centre (QIAGEN)

From: Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

  Average Ct Average Delta(Ct) (Ct(miROI) - Average Ct(normalisation factor)) 2^(−Average (Delta(Ct))
Mature
ID
Control Group Standard Deviation Group 1 Standard
Deviation
Control Group Standard Deviation Group 1 Standard Deviation Control Group Group 1
hsa-miR-181a-5p 24.99 0.804605 25.86 0.764923 5.146885 0.734814 6.241981 0.588011 0.028225 0.013212
RNU6–2 20.06 0.828910 20.90 0.754208 0.212599 0.610294 1.281648 0.640244 0.862981 0.411325